278 related articles for article (PubMed ID: 23953595)
1. In vitro evaluation of residual procoagulants in human intravenous immunoglobulins from 11 Chinese blood fractionation companies.
Ma L; Sun P; Lin F; Diao G; Li C
Thromb Res; 2013 Sep; 132(3):381-5. PubMed ID: 23953595
[TBL] [Abstract][Full Text] [Related]
2. Quantitative determination of activated coagulation factor XI as an impurity in therapeutic immunoglobulins from Chinese blood fractionation companies.
Ma L; Sun P; Lin FZ; Diao G; Li CQ
Genet Mol Res; 2013 Jul; 12(3):2556-61. PubMed ID: 23315876
[TBL] [Abstract][Full Text] [Related]
3. Identification of kallikrein and FXIa as impurities in therapeutic immunoglobulins: implications for the safety and control of intravenous blood products.
Etscheid M; Breitner-Ruddock S; Gross S; Hunfeld A; Seitz R; Dodt J
Vox Sang; 2012 Jan; 102(1):40-6. PubMed ID: 21545600
[TBL] [Abstract][Full Text] [Related]
4. A new manufacturing process to remove thrombogenic factors (II, VII, IX, X, and XI) from intravenous immunoglobulin gamma preparations.
Park DH; Kang GB; Kang DE; Hong JW; Lee MG; Kim KY; Han JW
Biologicals; 2017 Jan; 45():1-8. PubMed ID: 27876270
[TBL] [Abstract][Full Text] [Related]
5. Flebogamma(®) DIF (intravenous immunoglobulin) purification process effectively eliminates procoagulant activities.
José M; Marzo N; Pons B; Herrerias A; López L; Faro M; López M; Jorquera JI
Biologicals; 2013 Nov; 41(6):393-9. PubMed ID: 24051302
[TBL] [Abstract][Full Text] [Related]
6. Coagulation factor XI is a contaminant in intravenous immunoglobulin preparations.
Wolberg AS; Kon RH; Monroe DM; Hoffman M
Am J Hematol; 2000 Sep; 65(1):30-4. PubMed ID: 10936860
[TBL] [Abstract][Full Text] [Related]
7. Influence of coagulation factors on intrinsic thrombin generation.
Stief TW; Otto S; Renz H
Blood Coagul Fibrinolysis; 2007 Jan; 18(1):67-71. PubMed ID: 17179830
[TBL] [Abstract][Full Text] [Related]
8. Significance of platelet and monocyte activation for therapeutic immunoglobulin-induced thromboembolism.
Salge-Bartels U; Heiden M; Groß N; Seitz R
Thromb Res; 2014 Feb; 133(2):244-53. PubMed ID: 24342536
[TBL] [Abstract][Full Text] [Related]
9. Assessment of the ability of the Privigen® purification process to deplete thrombogenic factor XIa from plasma.
Komenda M; Stadler D; Malinas T; Moses M; Pragst I; Herzog E; Schmutz P; Minnig K; El Menyawi I
Vox Sang; 2014 Jul; 107(1):26-36. PubMed ID: 24329163
[TBL] [Abstract][Full Text] [Related]
10. The role of factor XI in a dilute thromboplastin assay of extrinsic coagulation pathway.
He R; Xiong S; He X; Liu F; Han J; Li J; He S
Thromb Haemost; 2001 Jun; 85(6):1055-9. PubMed ID: 11434684
[TBL] [Abstract][Full Text] [Related]
11. [Factor XIIa-inhibited diluted thromboplastin time can reflect coagulation process].
He S; Xiong S; He R; He X; Liu F; Han J; Li J
Zhonghua Xue Ye Xue Za Zhi; 2000 Mar; 21(3):118-21. PubMed ID: 11876967
[TBL] [Abstract][Full Text] [Related]
12. Effects of coagulation factor deficiency on plasma coagulation kinetics determined via thrombelastography: critical roles of fibrinogen and factors II, VII, X and XII.
Nielsen VG; Cohen BM; Cohen E
Acta Anaesthesiol Scand; 2005 Feb; 49(2):222-31. PubMed ID: 15715625
[TBL] [Abstract][Full Text] [Related]
13. Plasmin-induced procoagulant effects in the blood coagulation: a crucial role of coagulation factors V and VIII.
Ogiwara K; Nogami K; Nishiya K; Shima M
Blood Coagul Fibrinolysis; 2010 Sep; 21(6):568-76. PubMed ID: 20625277
[TBL] [Abstract][Full Text] [Related]
14. Early atherosclerosis exhibits an enhanced procoagulant state.
Borissoff JI; Heeneman S; Kilinç E; Kassák P; Van Oerle R; Winckers K; Govers-Riemslag JW; Hamulyák K; Hackeng TM; Daemen MJ; ten Cate H; Spronk HM
Circulation; 2010 Aug; 122(8):821-30. PubMed ID: 20697022
[TBL] [Abstract][Full Text] [Related]
15. Influence of coagulation factors on extrinsic thrombin generation.
Stief TW; Wieczerzak A; Renz H
Blood Coagul Fibrinolysis; 2007 Mar; 18(2):105-12. PubMed ID: 17287625
[TBL] [Abstract][Full Text] [Related]
16. Hypoperfusion in severely injured trauma patients is associated with reduced coagulation factor activity.
Jansen JO; Scarpelini S; Pinto R; Tien HC; Callum J; Rizoli SB
J Trauma; 2011 Nov; 71(5 Suppl 1):S435-40. PubMed ID: 22072000
[TBL] [Abstract][Full Text] [Related]
17. Contributions of procoagulants and anticoagulants to the international normalized ratio and thrombin generation assay in patients treated with warfarin: potential role of protein Z as a powerful determinant of coagulation assays.
Choi Q; Kim JE; Hyun J; Han KS; Kim HK
Thromb Res; 2013 Jul; 132(1):e70-5. PubMed ID: 23769659
[TBL] [Abstract][Full Text] [Related]
18. Cation exchange chromatography removes FXIa from a 10% intravenous immunoglobulin preparation.
Kang GB; Huber A; Lee J; Kim MJ; Bang E; Hong J; Park S
Front Cardiovasc Med; 2023; 10():1253177. PubMed ID: 38075963
[TBL] [Abstract][Full Text] [Related]
19. Absence of in vitro Procoagulant Activity in Immunoglobulin Preparations due to Activated Coagulation Factors.
Oviedo AE; Bernardi ME; Guglielmone HA; Vitali MS
Transfus Med Hemother; 2015 Nov; 42(6):397-402. PubMed ID: 26733772
[TBL] [Abstract][Full Text] [Related]
20. Assessment of immunoglobulin concentrates on thrombogenic activity by thrombin generation assay, prekallikrein activator assay, and size-exclusion chromatography.
Seifner A; Beck G; Bayer P; Eichmeir S; Lackner F; Rögelsperger O; Weber K; Wollein G
Transfusion; 2014 Feb; 54(2):376-83. PubMed ID: 23772713
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
